| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.125 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 1.125 | 0 | 0 | 215 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 7.549 | 2.444 | 42 | 3 | 18 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit/Loss - EUR | -6.424 | -2.444 | -42 | 211 | -18 | 0 | 0 | 0 | 0 | 0 |
| Net Profit/Loss - EUR | -6.458 | -2.444 | -42 | 205 | -18 | 0 | 0 | 0 | 0 | 0 |
| Employees | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Boboclin S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.469 | 0 | -42 | -3 | -21 | -21 | -20 | -20 | -20 | 0 |
| Current Assets | 139 | 37 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 141 | 37 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders Funds | -41.852 | -43.869 | -43.168 | -42.171 | -41.372 | -40.588 | -39.688 | -39.811 | -39.690 | -39.468 |
| Social Capital | 1.125 | 1.113 | 1.095 | 1.074 | 1.054 | 1.034 | 1.011 | 1.014 | 1.011 | 1.005 |
| Debts | 44.460 | 43.906 | 43.163 | 42.168 | 41.351 | 40.567 | 39.668 | 39.791 | 39.670 | 39.468 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8121 - 8121" | |||||||||
| CAEN Financial Year |
8122
|
|||||||||
Comments - Boboclin S.r.l.